Lupin also announced that USFDA has completed a post-marketing adverse drug experience (PADE) inspection of the company’s operations, which closed with no observations.
Lupin also announced that USFDA has completed a post-marketing adverse drug experience (PADE) inspection of the company’s operations, which closed with no observations. Lupin also announced that USFDA has completed a post-marketing adverse drug experience (PADE) inspection of the company’s operations, which closed with no observations. Moneycontrol Latest News Read More
